132 related articles for article (PubMed ID: 2190928)
1. Central and peripheral actions of a nonpeptidic angiotensin II receptor antagonist.
Koepke JP; Bovy PR; McMahon EG; Olins GM; Reitz DB; Salles KS; Schuh JR; Trapani AJ; Blaine EH
Hypertension; 1990 Jun; 15(6 Pt 2):841-7. PubMed ID: 2190928
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats.
Wood JM; Mah SC; Schnell C
J Cardiovasc Pharmacol; 1990; 16 Suppl 4():S60-4. PubMed ID: 1705630
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat.
Junggren IL; Zhao X; Sun X; Hedner T
J Pharm Pharmacol; 1996 Aug; 48(8):829-33. PubMed ID: 8887734
[TBL] [Abstract][Full Text] [Related]
6. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
Wienen W; Mauz AB; Van Meel JC; Entzeroth M
Mol Pharmacol; 1992 Jun; 41(6):1081-8. PubMed ID: 1614410
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316.
Olins GM; Corpus VM; McMahon EG; Palomo MA; Schuh JR; Blehm DJ; Huang HC; Reitz DB; Manning RE; Blaine EH
J Pharmacol Exp Ther; 1992 Jun; 261(3):1037-43. PubMed ID: 1602371
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.
Edwards RM; Aiyar N; Ohlstein EH; Weidley EF; Griffin E; Ezekiel M; Keenan RM; Ruffolo RR; Weinstock J
J Pharmacol Exp Ther; 1992 Jan; 260(1):175-81. PubMed ID: 1309870
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacology of SC-51316, a nonpeptidic angiotensin II receptor antagonist.
Olins GM; Smits GJ; Koepke JP; Huang HC; Reitz DB; Manning RE; Blaine EH
Am J Hypertens; 1993 Jul; 6(7 Pt 1):619-25. PubMed ID: 8398003
[TBL] [Abstract][Full Text] [Related]
13. Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus.
Yang RH; Jin H; Wyss JM; Oparil S
Hypertension; 1992 May; 19(5):475-81. PubMed ID: 1568766
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
Wong PC; Hart SD; Chiu AT; Herblin WF; Carini DJ; Smith RD; Wexler RR; Timmermans PB
J Pharmacol Exp Ther; 1991 Nov; 259(2):861-70. PubMed ID: 1941632
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist.
Wong YN; Wong PC
J Pharm Pharmacol; 1996 May; 48(5):492-7. PubMed ID: 8799873
[TBL] [Abstract][Full Text] [Related]
16. Conformationally restricted polysubstituted biphenyl derivatives with angiotensin II receptors antagonist properties.
Bovy PR; Collins JT; Olins GM; McMahon EG; Hutton WC
J Med Chem; 1991 Aug; 34(8):2410-4. PubMed ID: 1875338
[TBL] [Abstract][Full Text] [Related]
17. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
Ohlstein EH; Gellai M; Brooks DP; Vickery L; Jugus J; Sulpizio A; Ruffolo RR; Weinstock J; Edwards RM
J Pharmacol Exp Ther; 1992 Aug; 262(2):595-601. PubMed ID: 1501114
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.
Lee BH; Lee SH; Jung YS; Seo HW; Yoo SE; Shin HS
J Pharm Pharmacol; 1999 Oct; 51(10):1191-200. PubMed ID: 10579691
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor.
Mahon JM; Carr RD; Nicol AK; Henderson IW
J Hypertens; 1994 Dec; 12(12):1377-81. PubMed ID: 7706697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
